Class information for:
Level 1: VEMURAFENIB//BRAF INHIBITOR//BRAF

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1284 2744 45.9 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
375 3       MELANOMA//DERMATOLOGY//DERMATOL 32727
243 2             MELANOMA//MALIGNANT MELANOMA//DERMOSCOPY 19979
1284 1                   VEMURAFENIB//BRAF INHIBITOR//BRAF 2744

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 VEMURAFENIB authKW 1592243 8% 67% 213
2 BRAF INHIBITOR authKW 1389350 6% 78% 160
3 BRAF authKW 927884 13% 24% 347
4 DABRAFENIB authKW 862452 4% 78% 100
5 TRAMETINIB authKW 691302 3% 78% 80
6 MEK INHIBITOR authKW 522180 4% 46% 103
7 MELANOMA authKW 490096 28% 6% 776
8 NRAS authKW 452207 3% 43% 95
9 BRAF V600E authKW 248448 2% 33% 68
10 COBIMETINIB authKW 223028 1% 95% 21

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 29585 53% 0% 1467
2 Dermatology 14480 18% 0% 487
3 Cell Biology 1996 15% 0% 423
4 Pathology 1193 7% 0% 179
5 Chemistry, Medicinal 1184 7% 0% 188
6 Medicine, Research & Experimental 639 7% 0% 187
7 Pharmacology & Pharmacy 297 9% 0% 239
8 Genetics & Heredity 176 5% 0% 132
9 Biochemistry & Molecular Biology 85 10% 0% 265
10 Medical Laboratory Technology 37 1% 0% 24

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MELANOMA MED ONCOL 167235 3% 20% 76
2 SIGNAL TRANSDUCT TEAM 144849 1% 52% 25
3 CUTANEOUS ONCOL 83804 1% 18% 41
4 GENE ONCOGENE TARGETING TEAM 81926 0% 82% 9
5 MELANOMA AUSTRALIA 81366 1% 24% 30
6 MELANOMA 57199 1% 16% 32
7 SURG ONCOL MED ONCOL DERMATOL 55631 0% 100% 5
8 WESTMEAD CANC 49935 1% 11% 41
9 DERMATOL 45680 23% 1% 635
10 FOREMAN FDN MELANOMA 44493 0% 40% 10

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PIGMENT CELL & MELANOMA RESEARCH 160084 3% 16% 91
2 MELANOMA RESEARCH 38444 3% 4% 78
3 CANCER DISCOVERY 18910 1% 6% 28
4 CLINICAL CANCER RESEARCH 12332 5% 1% 129
5 MOLECULAR CANCER THERAPEUTICS 9760 2% 1% 60
6 THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 9329 0% 8% 11
7 JOURNAL OF INVESTIGATIVE DERMATOLOGY 5990 3% 1% 76
8 CANCER CELL 4508 1% 2% 25
9 JAMA DERMATOLOGY 3804 0% 3% 13
10 CANCER RESEARCH 3481 4% 0% 113

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 VEMURAFENIB 1592243 8% 67% 213 Search VEMURAFENIB Search VEMURAFENIB
2 BRAF INHIBITOR 1389350 6% 78% 160 Search BRAF+INHIBITOR Search BRAF+INHIBITOR
3 BRAF 927884 13% 24% 347 Search BRAF Search BRAF
4 DABRAFENIB 862452 4% 78% 100 Search DABRAFENIB Search DABRAFENIB
5 TRAMETINIB 691302 3% 78% 80 Search TRAMETINIB Search TRAMETINIB
6 MEK INHIBITOR 522180 4% 46% 103 Search MEK+INHIBITOR Search MEK+INHIBITOR
7 MELANOMA 490096 28% 6% 776 Search MELANOMA Search MELANOMA
8 NRAS 452207 3% 43% 95 Search NRAS Search NRAS
9 BRAF V600E 248448 2% 33% 68 Search BRAF+V600E Search BRAF+V600E
10 COBIMETINIB 223028 1% 95% 21 Search COBIMETINIB Search COBIMETINIB

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 SAMATAR, AA , POULIKAKOS, PI , (2014) TARGETING RAS-ERK SIGNALLING IN CANCER: PROMISES AND CHALLENGES.NATURE REVIEWS DRUG DISCOVERY. VOL. 13. ISSUE 12. P. 928 -+ 89 71% 117
2 CADINO, MS , LONG, GV , KEFFORD, RF , RIZOS, H , (2015) TARGETING ONCOGENIC BRAF AND ABERRANT MAPK ACTIVATION IN THE TREATMENT OF CUTANEOUS MELANOMA.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 96. ISSUE 3. P. 385 -398 127 84% 0
3 SOLUS, JF , KRAFT, S , (2013) RAS, RAF, AND MAP KINASE IN MELANOMA.ADVANCES IN ANATOMIC PATHOLOGY. VOL. 20. ISSUE 4. P. 217-226 99 74% 24
4 CAUNT, CJ , SALE, MJ , SMITH, PD , COOK, SJ , (2015) MEK1 AND MEK2 INHIBITORS AND CANCER THERAPY: THE LONG AND WINDING ROAD.NATURE REVIEWS CANCER. VOL. 15. ISSUE 10. P. 577 -592 95 57% 31
5 FEDORENKO, IV , GIBNEY, GT , SONDAK, VK , SMALLEY, KSM , (2015) BEYOND BRAF: WHERE NEXT FOR MELANOMA THERAPY?.BRITISH JOURNAL OF CANCER. VOL. 112. ISSUE 2. P. 217 -226 67 80% 30
6 SPAGNOLO, F , GHIORZO, P , ORGIANO, L , PASTORINO, L , PICASSO, V , TORNARI, E , OTTAVIANO, V , QUEIROLO, P , (2015) BRAF-MUTANT MELANOMA: TREATMENT APPROACHES, RESISTANCE MECHANISMS, AND DIAGNOSTIC STRATEGIES.ONCOTARGETS AND THERAPY. VOL. 8. ISSUE . P. 157 -168 72 77% 26
7 SPAGNOLO, F , GHIORZO, P , QUEIROLO, P , (2014) OVERCOMING RESISTANCE TO BRAF INHIBITION IN BRAF-MUTATED METASTATIC MELANOMA.ONCOTARGET. VOL. 5. ISSUE 21. P. 10206 -10221 72 88% 23
8 EL-NASSAN, HB , (2014) RECENT PROGRESS IN THE IDENTIFICATION OF BRAF INHIBITORS AS ANTI-CANCER AGENTS.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. VOL. 72. ISSUE . P. 170-205 94 72% 13
9 TRAN, KA , CHENG, MY , MITRA, A , OGAWA, H , MAVERAKIS, E , KLOXIN, AM , OLNEY, LP , SHI, VY , (2016) MEK INHIBITORS AND THEIR POTENTIAL IN THE TREATMENT OF ADVANCED MELANOMA: THE ADVANTAGES OF COMBINATION THERAPY.DRUG DESIGN DEVELOPMENT AND THERAPY. VOL. 10. ISSUE . P. 43 -52 68 78% 4
10 CHENG, YB , ZHANG, GH , LI, G , (2013) TARGETING MAPK PATHWAY IN MELANOMA THERAPY.CANCER AND METASTASIS REVIEWS. VOL. 32. ISSUE 3-4. P. 567 -584 98 61% 22

Classes with closest relation at Level 1


Rank Class id link
1 35107 DIARYLAMIDE//DIARYLUREA//A375P
2 11748 RAF//LEO JENKINS CANC//KSR1
3 23426 CELLULAR HEMOSTASIS//NEVOCELLULAR NEVI//SKIN DIS PROGRAM
4 6326 METASTATIC MELANOMA//BIOCHEMOTHERAPY//DACARBAZINE
5 721 PD L1//PD 1//IPILIMUMAB
6 19838 MIR 203//MIR 137//MICRORNA 203
7 3413 PAPILLARY THYROID CARCINOMA//RET PTC//BRAFV600E MUTATION
8 2234 PANITUMUMAB//CETUXIMAB//KRAS
9 3965 EVOLUT CANC//CANCER GENOME//CANCER GENOMICS
10 16698 TRICHOMEGALY//EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS//SKIN TOXICITY

Go to start page